loading page

Trends in race and sex reporting in lung cancer phase III clinical trials
  • +2
  • Faaiq Aslam,
  • Rami Manochakian,
  • Yanyan Lou,
  • Gerardo Colon-Otero,
  • Taimur Sher
Faaiq Aslam
Mayo Clinic Alix School of Medicine
Author Profile
Rami Manochakian
Mayo clinic
Author Profile
Yanyan Lou
Mayo clinic
Author Profile
Gerardo Colon-Otero
Mayo Clinic Florida
Author Profile
Taimur Sher
Mayo Clinic

Corresponding Author:[email protected]

Author Profile


Background: To understand the changing trends in reporting of race and sex as a demographic variable in phase III lung cancer clinical trials published over the last 35 years. Methods: A total of 426 articles reporting results of phase 3 lung cancer clinical trials published from 1984 to 2019 were identified in PubMed. Statistical analysis on trends over time on percentage of minority and female participation were performed. Results: Only 137 (32.2%) of the 426 studies analyzed reported race of participants. Among those studies, we found that the mean participation rate of white participants was significantly higher (82.65%) (p < 0.001). We found a decrease in African American participants and an increase in Asian participants over time. When looking at sex, we found that although the rate of male participation (69.02%) was significantly higher than that of female participation (30.98%), the female participation has improved with time at a rate of 0.65% per year. Conclusions: We found that the reporting and participation of minority races continues to lag that of other demographic factors like sex in phase III clinical trials in lung cancer. Especially in African Americans, where the participation in lung cancer phase III clinical trials has declined despite the rising incidence in lung cancer.
22 Apr 2023Submitted to Cancer Reports
24 Apr 2023Submission Checks Completed
24 Apr 2023Assigned to Editor
24 Apr 2023Review(s) Completed, Editorial Evaluation Pending
25 Apr 2023Reviewer(s) Assigned
26 May 2023Editorial Decision: Revise Minor
09 Jun 20231st Revision Received
12 Jun 2023Submission Checks Completed
12 Jun 2023Assigned to Editor
12 Jun 2023Review(s) Completed, Editorial Evaluation Pending
12 Jun 2023Reviewer(s) Assigned
12 Jun 2023Editorial Decision: Accept